Allarity Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Allarity Therapeutics
ALLR Stock  USD 1.21  0.07  6.14%   
Allarity Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Allarity Therapeutics' valuation are provided below:
Gross Profit
-36.3 M
Market Capitalization
17.3 M
Revenue
-7.1 M
Earnings Share
5.75
Revenue Per Share
(0.02)
There are over one hundred nineteen available fundamental signals for Allarity Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Allarity Therapeutics' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/15/2026, Market Cap is likely to drop to about 2.1 M. In addition to that, Enterprise Value is likely to grow to about (17.8 M)

Allarity Therapeutics Total Revenue

0.0

Check Allarity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allarity Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 K, Other Operating Expenses of 32.9 M or Cost Of Revenue of 7.7 K, as well as many indicators such as Price To Sales Ratio of 6.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.17. Allarity financial statements analysis is a perfect complement when working with Allarity Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Allarity Stock
Check out the analysis of Allarity Therapeutics Correlation against competitors.
To learn how to invest in Allarity Stock, please use our How to Invest in Allarity Therapeutics guide.

Allarity Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets19.9 M26 M15.5 M
Slightly volatile
Short and Long Term Debt Total1.6 M1.6 M1.5 M
Slightly volatile
Other Current Liabilities3.5 M6 M2.8 M
Slightly volatile
Total Current Liabilities7 M12.5 M5.6 M
Slightly volatile
Cash23.6 M22.5 M5.5 M
Slightly volatile
Non Current Assets Total337.6 K355.4 K8.9 M
Pretty Stable
Other Assets0.210.220.4159
Slightly volatile
Cash And Short Term Investments23.6 M22.5 M5.6 M
Slightly volatile
Common Stock Shares Outstanding1.9 M1.8 M317.6 K
Slightly volatile
Liabilities And Stockholders Equity19.9 M26 M15.5 M
Slightly volatile
Total Liabilities9.2 M12.5 M7.2 M
Slightly volatile
Total Current Assets27 M25.7 M7 M
Slightly volatile
Short Term Debt1.3 M1.6 M1.3 M
Slightly volatile
Intangible Assets15.7 M11.4 M12.7 M
Slightly volatile
Common Stock1.1 K1.1 K262.7 K
Very volatile
Net Receivables1.6 M2 M1.4 M
Pretty Stable
Good Will1.7 M1.7 M2 M
Slightly volatile
Other Current Assets735.5 K521.1 K867.5 K
Pretty Stable
Property Plant And Equipment Net373.1 K355.4 K148.5 K
Slightly volatile
Accounts Payable3.4 M4.8 M2.5 M
Slightly volatile
Property Plant Equipment18 K18.9 K393.4 K
Very volatile
Other Liabilities298.4 K314.1 K19.3 M
Slightly volatile
Long Term Investments488.4 K402.5 K265.1 K
Slightly volatile
Property Plant And Equipment Gross293.3 K278.1 K547.9 K
Slightly volatile
Short and Long Term Debt1.6 M1.6 M1.1 M
Slightly volatile
Capital Stock855900944.5 K
Pretty Stable
Long Term Debt1.1 M1.2 M954.8 K
Slightly volatile
Current Deferred Revenue50.4 K53.1 K6.1 M
Slightly volatile
Warrants1.6 M1.8 M2 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Capital Surpluse66.5 M74.8 M81.7 M
Slightly volatile
Deferred Long Term Liabilities1.1 M1.3 M1.4 M
Slightly volatile

Allarity Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.7 K8.1 K76.3 K
Slightly volatile
Other Operating Expenses32.9 M31.3 M12.6 M
Slightly volatile
Cost Of Revenue7.7 K8.1 K735.8 K
Pretty Stable
Total Operating Expenses32.9 M31.3 M12.2 M
Slightly volatile
Interest Expense656.1 K751 K445.2 K
Slightly volatile
Selling General Administrative9.5 M13.2 M6.4 M
Slightly volatile
Research Development8.2 M7 M6.9 M
Pretty Stable
Reconciled Depreciation7.7 K8.1 K45.7 K
Slightly volatile
Preferred Stock And Other Adjustments4 M4.5 M4.9 M
Slightly volatile
Non Recurring14.1 M15.8 M17.3 M
Slightly volatile
Non Operating Income Net Other13.5 M15.2 M16.6 M
Slightly volatile

Allarity Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation7.7 K8.1 K131.5 K
Slightly volatile
End Period Cash Flow23.6 M22.5 M6.1 M
Slightly volatile
Begin Period Cash Flow181.4 K190.9 K2.4 M
Very volatile
Issuance Of Capital Stock48.7 M46.3 M20.1 M
Slightly volatile
Dividends Paid6.9 M12.6 M3.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.1 K6.4 K304 M
Slightly volatile
Days Sales Outstanding4.8 K4.5 K2.7 K
Slightly volatile
Invested Capital63.1 K71 K77.5 K
Slightly volatile
Stock Based Compensation To Revenue2.622.52.0408
Slightly volatile
Capex To Depreciation31.2929.87.6731
Slightly volatile
Inventory Turnover10.5211.8312.915
Slightly volatile
Days Of Inventory On Hand22.2124.9927.2732
Slightly volatile
Payables Turnover4.033.013.7034
Slightly volatile
Sales General And Administrative To Revenue25.829.0331.6812
Slightly volatile
Research And Ddevelopement To Revenue42.4547.7552.1221
Slightly volatile
Capex To Revenue0.07280.07670.2565
Slightly volatile
Cash Per Share10.3910.94175.6 K
Pretty Stable
Days Payables Outstanding86.87126106
Slightly volatile
Income Quality1.160.811.2538
Slightly volatile
Intangibles To Total Assets0.580.750.7367
Very volatile
Current Ratio1.742.372.0662
Slightly volatile
Receivables Turnover0.07910.08325.2821
Pretty Stable
Capex Per Share0.160.17294
Pretty Stable
Average Receivables193.7 K184.5 K137.9 K
Slightly volatile
Revenue Per Share1.5 K1.4 K1.1 K
Slightly volatile
Interest Debt Per Share1.361.4395.8 K
Pretty Stable
Debt To Assets0.06360.05360.0677
Slightly volatile
Operating Cycle4.8 K4.5 K2.7 K
Slightly volatile
Days Of Payables Outstanding86.87126106
Slightly volatile
Ebt Per Ebit0.991.050.9733
Slightly volatile
Long Term Debt To Capitalization0.340.330.1291
Slightly volatile
Quick Ratio1.732.372.0582
Slightly volatile
Net Income Per E B T0.710.890.8395
Slightly volatile
Cash Ratio1.212.071.6791
Slightly volatile
Days Of Inventory Outstanding22.2124.9927.2732
Slightly volatile
Days Of Sales Outstanding4.8 K4.5 K2.7 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.171.0269
Slightly volatile
Fixed Asset Turnover0.30.326.4814
Very volatile
Debt Ratio0.06360.05360.0677
Slightly volatile
Price Sales Ratio6.1 K6.4 K304 M
Slightly volatile
Asset Turnover0.00320.00340.0816
Slightly volatile

Allarity Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 M2.2 M398.1 M
Slightly volatile

Allarity Fundamental Market Drivers

Allarity Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Allarity Therapeutics Financial Statements

Allarity Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Allarity Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Allarity Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Allarity Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue53.1 K50.4 K
Cost Of Revenue8.1 K7.7 K
Stock Based Compensation To Revenue 2.50  2.62 
Sales General And Administrative To Revenue 29.03  25.80 
Research And Ddevelopement To Revenue 47.75  42.45 
Capex To Revenue 0.08  0.07 
Revenue Per Share1.4 K1.5 K
Ebit Per Revenue(168.77)(160.33)

Pair Trading with Allarity Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allarity Stock

  0.77LIPO Lipella PharmaceuticalsPairCorr

Moving against Allarity Stock

  0.83DD Dupont De NemoursPairCorr
  0.8CSCO Cisco SystemsPairCorr
  0.79TRV The Travelers Companies Earnings Call This WeekPairCorr
  0.76AMGN Amgen IncPairCorr
  0.73WSFS WSFS FinancialPairCorr
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY